



27

## Abstract

28 **Background:** Research Ethics Committees (RECs) review the ethical, legal, and methodological  
29 standard of clinical research. However, complying with all requirements and professional  
30 expectations while maintaining the necessary scientific and ethical standards can be challenging for  
31 applicants and members of the REC alike. There is a need for accessible guidelines and resources to  
32 help medical researchers and REC members navigate the legal and ethical requirements and the  
33 process of their review. **Methods:** We employed an explorative search for resources on the websites  
34 of a purposively selected sample of relevant stakeholders including 12 national umbrella  
35 organizations (six German-language and six English-language), three English-language international  
36 umbrella organizations, and 16 national REC's of major university hospitals (eight German- and eight  
37 English-language). We qualitatively mapped the identified resources onto the guiding principles of  
38 ethical clinical research and 35 related checkpoints. To describe the content of the resources we  
39 conducted a thematic analysis. **Results:** We extracted a total of 233 resources, including templates  
40 ( $n = 134$ , 58.5%), guidelines/recommendations ( $n = 62$ , 26.6%), checklists ( $n = 23$ , 9.9%), tools ( $n = 5$ ,  
41 2.2%), flowcharts ( $n = 5$ , 2.2%), glossaries ( $n = 3$ , 1.3%), and one (0.4%) software program. We  
42 extracted 101 German and 132 English resources created between 2004 and 2023. The majority ( $n =$   
43 204; 87.6%) could be assigned to one checkpoint. The remaining 29 (12.5%) resources were  
44 considered unspecific (e.g., a checklist which documents to be submitted for a German drug trial).  
45 The specific resources are discussed per checkpoint.

46 **Conclusion:** While much support is available for some aspects such as participant information and  
47 informed consent forms, it is lacking in other areas such as study design, analysis, and biometrics.  
48 More support should be provided in these areas to ensure that research projects are  
49 methodologically sound. A more detailed analysis of the quality of available resources could help  
50 identify other areas of need.

51 **Keywords:** research ethics, clinical trials, resources, guidance

52

53

54

55

## Background

56

57

58

59

60

61

62

63

64

Human clinical research plays a central role in the development and validation of therapies (including drugs, biologics, medical devices) and diagnostics (1). To ensure that clinical trials involving human participants meet the highest standards of research ethics, they must be reviewed by an institutional review board (IRB) or research ethics committees (RECs)<sup>1</sup>. Although there are some international differences in responsibilities (2), RECs generally evaluate clinical trials for ethical justification, including the risks and benefits to study participants, the informed consent documents, scientific validity, and methodological soundness including aspects of the study design and statistical analysis (3–6). Consequently, RECs are of vital importance for the ethical, legal, and methodological standard of clinical research.

65

66

67

68

69

70

71

72

73

The quality of the ethical review hinges on the quality of the documents provided by the applicants and the ability of members of RECs to evaluate these. The quality of the documents in turn depends on the applicant's ability to navigate a complex landscape of ethical, legal, and methodological requirements. Members of RECs on the other hand must handle these aspects in a responsible and fair manner. Some aspects are governed by international law, others by federal or state law, and some refer to non-legal professional laws and guidelines such as the Declaration of Helsinki (4) or CIOMS guidelines (5). Furthermore, ethical judgements on the appropriateness of consent documents or risk-benefit ratios require expert knowledge and, unavoidably, include interpretive judgments.

74

75

76

Complying with all legal requirements and further professional expectations while maintaining the necessary scientific and ethical standards can be challenging for applicants and members of the REC alike. Consequently, there is a need for accessible guidelines and resources to

---

<sup>1</sup> The term IRB is more commonly used in America. In this article, we will use the term REC, which is more common in Europe.

77 help medical researchers and REC members navigate the legal and ethical requirements and the  
78 process of their review. Ideally, such guidance and resources should be easily accessible and readily  
79 available, enabling applicants to incorporate them into early study planning and ethics application  
80 drafting. s Assuming that the first point of contact for applicants prior to the ethics application is the  
81 websites of ethics committees and their umbrella organizations, their websites serve as the optimal  
82 platform for distributing resources to applicants before they submit their ethics applications.

83 Several types of resources could facilitate the application and review process, including  
84 checklists, templates, topic-specific guidelines, decision trees or online tools<sup>2</sup>. For example,  
85 checklists could ensure that all required information is included in the application avoiding  
86 unnecessary effort, such as the need to resubmit application. Templates could streamline the  
87 application and review process, for example ensuring that informed consent texts meet all legal  
88 requirements. REC members could also benefit from using REC-approved templates, for example by  
89 saving time and focusing only on the highlighted changes during the assessment.

90 Many umbrella organizations and RECs already offer online resources for applicants and REC  
91 members. For example, the German association of RECs (Arbeitskreis Medizinischer Ethik-  
92 Kommissionen, AKEK) or the World Health Organization (WHO) offer guidelines and templates  
93 online to aid the application process (7,8). However, these individual resources are spread across  
94 many websites, making it opaque what the existing resources offer. A scoping review in Pubmed and  
95 Google on “Resources to Aid Ethical Review of Clinical Studies” did not reveal a systematically  
96 developed overview of available resources. It is therefore unclear to what extent the available  
97 resources cover aspects of clinical research ethics.

98 The aim of this project is to explore and qualitatively describe the pool of available resources  
99 to answer the question of which types of resources are already available and which topics they  
100 cover. Our search is not intended to identify all available resources, but to give a qualitative,

---

<sup>2</sup> Note that we have intentionally excluded textbooks and published papers from this list, as they are not as readily accessible and require a greater time commitment that is rarely achievable in application and review procedures for individual clinical studies.

101 thematically saturated overview of what types of resources are commonly available. Therefore, we  
102 focused our search on the websites of a purposively selected sample of relevant stakeholders  
103 including umbrella organizations of RECs and RECs of major university hospitals and limited  
104 ourselves to German- and English-language resources. We have selected these groups because we  
105 believe that they are the first point of contact for applicants and REC members when faced with  
106 issues regarding research ethics in clinical trial as well as the process of writing or reviewing an  
107 ethics application.

## 108 **Methods**

### 109 **Protocol and Registration**

110 This dynamic, data-driven project, was not preregistered. Instead, we provide a project log  
111 and all relevant material on OSF (<https://osf.io/e7dmt/>).

### 112 **Search and Selection of Sources**

113 We searched for online resources provided by national and international umbrella  
114 organisations for clinical research ethics as well as RECs of large university hospitals in Germany, the  
115 United States, and the United Kingdom (see Table 1). The project started in February 2023. We  
116 created a list of potential sources from personal experience and expertise. We then searched the  
117 websites of relevant umbrella organizations also applying backward searching, examining relevant  
118 stakeholders when they were mentioned on the websites of the umbrella organizations. Next, we  
119 searched the websites of RECs of major university hospitals. On each individual website, we first  
120 opened all subtabs linked to from the starting website. We then went through each subpage  
121 successively and searched for resources relating to ethics. The search was stopped in August 2023  
122 when we reached saturation defined as encountering the same kind of resources (e.g., templates for  
123 informed consent) without being able to add untapped resources to the collection. A detailed log of  
124 the search including considerations and justifications for the inclusion and exclusion of stakeholders  
125 can be found on OSF (<https://osf.io/usbt8>). Due to the use of backwards searching the final selection

126 of sources also included related umbrella organizations (e.g., Clinical Research Ethics Consultation  
127 Collaborative) and not only umbrella organizations or RECs.

### 128 **Information Sources**

129 We identified 31 information sources (Table 1) including 12 national umbrella organizations,  
130 three international umbrella organizations, and 16 national REC's.

### 131 **Eligibility Criteria**

132 We limited ourselves to German- and English-language resources but employed liberal  
133 eligibility criteria. To be extracted, resources had to relate to the application for ethical approval for  
134 clinical studies. Clinical studies could be mono- or multi-site studies, trials testing medical products,  
135 drugs, or other medical interventions with human participants. Resources could be of several types  
136 (i.e., checklists, templates, flowcharts, or recommendations) and be addressed to the applicants (i.e.,  
137 applied researchers), REC members, or both. We did not extract resources in the form of legal texts,  
138 tutorials for university-specific submission programs, or course syllabi. To avoid duplication, we did  
139 not extract resources if they were already extracted from a previous source.<sup>3</sup>

### 140 **Data Items**

141 For each resource, we extracted: the stakeholder and their main website, country, year of  
142 publication, type of study if applicable, type of resource, the link to the resource, a description of the  
143 resource, and language. The extraction sheet was piloted with a selection of resources from the first  
144 stakeholder considered (i.e., AKEK) and adjusted accordingly.

### 145 **Data Charting Process and Synthesis**

146 To qualitatively describe the resources, we mapped them onto the guiding ethical principles  
147 of an internationally established framework for clinical research, namely, social value, scientific  
148 validity, favorable risk-benefit ratio, fair participant selection, independent review, informed  
149 consent, respect for participants, and collaborative partnership (see Emanuel et al., 2008) and 35

---

<sup>3</sup> Note that this limits the comparability of the number of resources between sources as we did not count the number of all resources available but the number of resources, not yet presented at previously extracted sources.

150 related checkpoints presented in Raspe et al. (2012). The 35 checkpoints (Figure 1) provide a more  
151 detailed and praxis-oriented account of how the guiding principles are translated into the ethical  
152 review process.

153 If possible, resources were assigned to one of the 35 checkpoints during extraction. If no  
154 clear assignment was possible, the resource was grouped under 'other'. During data analysis, we  
155 checked whether this initial assignment was congruent with the content of the resource. This  
156 resulted in 21 resources being relabeled (see the project log provided on OSF).

157 To describe the available resources, the first author (MMP) conducted a thematic analysis in  
158 Atlas.ti using thematic analysis as a realist method. Themes were identified at the semantic level  
159 from the content explicitly mentioned in the resources. We used a deductive approach by having the  
160 checkpoints guide our qualitative analysis and theme construction. First, documents were grouped  
161 according to the checkpoints assigned during data extraction. Next, the resources for the first ten  
162 checkpoints were coded to create a codebook. The overall structure of the codebook was  
163 continuously revised during this process. Following, the revised codebook structure (i.e., authors,  
164 target group, resource type, main topic, topic, language, study type, participant type, data type, and  
165 legal regulations) was used to code all resources. While additional subcodes were added during this  
166 stage, the overall theme structure remained.

## 167 **Results**

168 We initially extracted 243 resources from the websites of 24 stakeholders<sup>4</sup> (see Table 1)  
169 reflecting umbrella organizations of RECs and RECs of major university hospitals. During data  
170 analysis, we excluded ten resources (nine due to eligibility criteria and one duplicate). This resulted  
171 in a total of 233 resources. The majority ( $n = 204$ ; 87.6%) could be assigned to one checkpoint. The  
172 remaining 29 (12.5%) resources were considered unspecific (e.g., a checklist which documents to be  
173 submitted for a German drug trial).

---

<sup>4</sup> For seven stakeholders, we did not find any additional resources to extract.

174 Resources included templates ( $n = 134$ , 58.5%), guidelines/recommendations ( $n = 62$ ,  
175 26.6%), checklists ( $n = 23$ , 9.9%), tools ( $n = 5$ , 2.2%), flowcharts ( $n = 5$ , 2.2%), glossaries ( $n = 3$ , 1.3%),  
176 and one (0.4%) software program. We extracted 101 German resources and 132 English resources.  
177 Resources were created between 2004 and 2023 with more resources being created or updated  
178 recently (see Figure 2.)

### 179 **Qualitative Description of Resources**

180 Below, we provide a brief overview of the available resources per checkpoint. A more  
181 detailed overview of the available resources per checkpoint and the themes they cover is presented  
182 in Table 2 and the full list of all available resources can be found in the supplement. Following the  
183 structure proposed by Raspe and colleagues (10) we grouped checkpoints and resources under the  
184 headings of (1) study governance/management [ $n = 24$ , 10.30%], (2) research question and study  
185 design [ $n = 32$ , 13.73%], (3) study participants [ $n = 99$ , 40.77%], and (4) documentation, analysis, and  
186 dissemination [ $n = 49$ , 21.03%] (see Figure 1). The remaining 29 (12.45%) resources were grouped  
187 under 'other'.

### 188 **Study Governance/Management.**

189 The topic "Study Governance/Management" covers the broad set of activities of principal  
190 investigators (PIs), sponsors or other staff involved in managing and governing a specific clinical  
191 study. Our search revealed supporting resources for most but not all the checkpoints grouped under  
192 this topic (5/8; 62.50%).

193 Support was offered regarding the qualifications of study management, investigators, and  
194 study sites ( $n = 14$ ), the implementation of multi-site studies ( $n = 5$ ) with a specific focus on ancillary  
195 review, the collaboration between study management and sponsors ( $n = 2$ )<sup>5</sup>, the transparent  
196 calculation and tracking of study financing ( $n = 2$ ), and the reporting of conflict of interests ( $n = 1$ ).

---

<sup>5</sup> Our search suggests that some RECs such as for example the University Hospital Bristol and University Hospital Birmingham offer institution specific resources regarding sponsorship. These did not meet our inclusion criteria but are presented in the data file on OSF under 'other resources'.



197 Our search revealed no resources to support the creation of an appropriate study title, study  
198 registration, and notification of authorities, the identification of relevant legal regulations, or the  
199 composition or creation of study committees.

#### 200 **Research Question and Study Design.**

201 The topic “Research Question and Study Design” covers conceptual and methodological  
202 aspects of the study development and design. Our search revealed resources to support only the  
203 minority (4/11; 36.36%) of the checkpoints grouped under this topic.

204 Support was offered for the design and organization of study protocols (n = 23) including  
205 resources offering universal support or targeting specific study designs or data collection methods,  
206 the selection and specifically the recruitment of participants (n = 7), the risk assessment of an  
207 intervention in a clinical study involving therapies of medicinal products, and the reporting of trial  
208 termination to the responsible REC (n = 1).

209 Our search revealed no resources to support the other checkpoints relating to study design.  
210 Namely, the research question, background, objective, hypothesis, and target population, the  
211 summary of the current state of knowledge, sample size calculation, the study type and study  
212 design, the control group/intervention, blinding, and the study outcomes.

#### 213 **Study Participants**

214 The topic “Study Participants” covers aspects related to the safety and compensation of  
215 study participants. Our search revealed resources to support the majority (6/7; 85.71%) of the  
216 checkpoints grouped under this topic.

217 Specifically, support was offered for the preparation of participant information and informed  
218 consent forms (n = 74) including resources offering universal support or targeting specific study  
219 designs, participant types, or situations, the inclusion and treatment of members of vulnerable  
220 groups (n = 8), aspects related to insurance (n= 6), the development of informed consent strategies

221 for participants that are incapable of providing consent (n = 5), the collection and storage of  
222 biological or genetic material (n = 3)<sup>6</sup>, and the financial compensation for participation (n = 1)<sup>7</sup>.

223 Our search did not yield results for resources to support setting up medical care or  
224 psychosocial support for study participants.

### 225 **Documentation, Analysis, Reporting**

226 The topic “Documentation, Analysis, Reporting” covers aspects relating the documentation,  
227 storage, and sharing of data, methods, and results. Our search revealed resources to support the  
228 majority (7/8; 87.50%) of the checkpoints grouped under this checkpoint.

229 Specifically, support was offered for the documentation and reporting of adverse events and  
230 side effects (n = 14), the collection (n = 5) protection (n = 10), and preservation of data (n = 9),  
231 documentation purposes (n = 9), and the analysis (n = 1) and reporting (n = 1) of study results.

232 Our search did not reveal any resources to control study implementation.

### 233 **Other**

234 We extracted an additional 29 resources ( $n_{\text{English}} = 18$ ,  $n_{\text{German}} = 11$ ) that could not be grouped  
235 under one of the checkpoints. This included 12 checklists, nine guidelines, five templates, two tools,  
236 and one flowchart. The checklists concerned the required documents to be submitted for several  
237 types of studies, evaluation of the application or study protocol, continuing review, human research  
238 determination, project closure and the use of templates (from swissethics). Guidelines targeted the  
239 evaluation of applications, the obligation to report changes to the study protocol to the REC, human  
240 research determination, guidance how to apply through the online portal ethikPool or a compilation  
241 of international human research standards. The tools offered online training for clinical research  
242 ethics and the flowchart could be used to find answers to ethical questions that might arise during  
243 the research process.

---

<sup>6</sup> Please note that the collection of biological materials was addressed in 13 additional resources including informed consent templates, insurance templates, and templates for participant information, which are grouped under different checkpoints.

<sup>7</sup> However, financial arrangements and compensation was also mentioned in two additional resources. Guideline R134 grouped under participant recruiting explores the option of financial compensation and template R217 grouped under study financing has a section for financial arrangements.

244 **Discussion**

245 **Resource Landscape**

246 At the searched websites of umbrella organizations and RECs of major university hospitals  
247 we found a broad spectrum of resources supporting clinical researchers and members of RECs, most  
248 of which were templates, followed by guidelines and checklists.

249 Support varied between different checkpoints. Various types of resources are available for  
250 some aspects such as the preparation and assessment of participant information and consent form  
251 for different participant groups, subject areas (e.g., language, surrogate decision makers, etc.), and  
252 legal contexts, the preparation of study protocols, the assessment of qualifications of investigators  
253 and study sites, the reporting and documentation of adverse events, and data protection.  
254 Nonetheless, support is lacking in other areas (i.e., study design, analysis, and biometrics).

255 **Gaps**

256 In some instances, there are reasonable explanations for a lack of resources. For example,  
257 umbrella organizations and RECs offered limited support for trial registrations, instead providing  
258 links to registry websites possibly under the assumption that registries should provide resources for  
259 trial registration, as the DRKS [Deutsches Register Klinischer Studien] and [clinicaltrials.gov](https://clinicaltrials.gov) do  
260 (11,12)). However, this dispersion of information may pose a risk, making it time-consuming for  
261 applicants to find the necessary support and potentially explain some of the reported shortcomings  
262 of trial registrations (Thiele & Hirschfeld, 2022; Viergever).

263 Similarly, the searched websites did not provide resources to help researchers navigate the  
264 legal texts that govern many types of clinical trials. Instead, stakeholders frequently referred to the  
265 legal texts in full. As some legal requirements for clinical trials are reflected by checkpoints (e.g.,  
266 qualification of the principal investigator), it is understandable that there were no resources  
267 specifically assigned to this checkpoint. Nonetheless, we believe that researchers could benefit from  
268 interpretive aids or checklists of the requirements arising from the legal regulatory framework.

269 This review also identified important gaps in the existing resources provided by the searched  
270 stakeholders in areas related to study design and biometrics. Few to no resources were found for  
271 these aspects. It is possible that this expertise resides outside of ethics. In contrast to other aspects,  
272 however, stakeholders did not refer to existing structures such as clinical study coordination systems  
273 or methodological and/or statistical consultation offered by university hospitals, which might be  
274 helpful for researcher to become aware of these services and seek them out. However, even then,  
275 the psychological barrier of a personal consultation may be high, which raises the question of the  
276 extent to which these services would be used. The need for simple, understandable, and easy-to-use  
277 resources on the topic of study design and biometrics for clinical research in humans, as for example  
278 available for animal research (e.g., the Experimental Design Assistant (15)), remains.

279 Even for checkpoints with resources available, it remains open whether these indeed cover  
280 all relevant topic areas. For example, participant selection does not only concern the recruitment  
281 but also judgements regarding the representativeness of the participant pool, and appropriate in-  
282 and exclusion criteria. However, we did not find resources addressing these aspects of participant  
283 selection. Similarly, there is a scarcity of resources supporting the reporting of conflict of interest  
284 (Col), despite tools developed by other stakeholders like journals and publishers to facilitate Col  
285 statement creation (e.g., <https://declarations.elsevier.com/>).

## 286 **Opportunities**

287 This project highlights opportunities for advancing and refining resources to support the  
288 clinical research ethics application process. The primary project output is a comprehensive overview  
289 of resources provided by key stakeholders. This overview can be used (1) for further tool and  
290 resource development and (2) a database for future research evaluating their quality and alignment  
291 with the needs of applicants and REC members.

292 Ultimately, these resources aim to enhance the quality of the ethical review process for all  
293 stakeholders, including applicants, REC members, and research participants. Presently, there are no  
294 established measures to evaluate quality and effectiveness of RECs (16). This is likely because the

295 process of research ethics applications and approvals are based on ethical and regulatory standards  
296 that are subjectively applied (17). In the absence of effectiveness measures, tools, templates,  
297 checklists, and other resources can improve the clinical ethical review process. At the very least,  
298 systematic use of resources enhances efficiency of the review process and ensures compliance with  
299 regulatory and institutional policies, key quality indicators often mentioned by REC directors (Lynch  
300 et al., 2022). At best, the use of tools and resources for REC applications and decision-making  
301 procedures enables thoughtful engagement with the procedure of REC decision making and  
302 promotes consistent and robust standards (see for example Seykora et al., 2021).

### 303 **Limitations**

304 Although this review has covered many prominent and relevant stakeholders, we recognize  
305 that our results do not cover all resources available to clinical researchers and REC members. Some  
306 information may be located on websites of stakeholders that were not included, other information  
307 may be shared internally, through password-protected pages, and other resources are likely  
308 available on websites of other organization types not included in this review. Additionally, the scope  
309 of our review was determined by thematic saturation. However, increased redundancy in some  
310 topics does not mean that there are not some resources on other topics on websites that we did not  
311 look at. We therefore highlight that this was a first scoping review exploring what kind of resources  
312 are provided at RECs and related umbrella organizations and should not be viewed as a  
313 comprehensive assessment of *all* available resources.

314 We caution against viewing our resource collection as a recommendation. In our qualitative  
315 analysis, we noticed markable variation in the depth and quality of different resources, but accuracy  
316 and timeliness were not examined. The qualitative value of the available resources remains unclear.  
317 Further detailed analysis and user testing are needed, but beyond the scope of this paper.

318 Lastly, we did not differentiate between supporting templates and forms required by the  
319 REC or (national) law. While we label forms as such in the amendment, we did not treat them as a  
320 separate category in the analysis, as forms can be considered supportive as they enhance

321 transparency and the systematic nature of the research ethics application, facilitating understanding  
322 and compliance. This distinction may be explored in future research.

### 323 **Conclusion**

324 This project provided an initial overview of the resources available to support applicants and  
325 REC members. We hope that this project will stimulate greater engagement with available resources  
326 and the identified thematic gaps, both in consultation with relevant stakeholder groups.

### 327 **Declarations**

328 **Ethics approval and consent to participate:** Not applicable

329 **Consent for publication:** Not applicable

330 **Availability of data and materials:** The datasets generated and analysed during the current study  
331 are available in the OSF repository, <https://osf.io/e7dmt/>, DOI 10.17605/OSF.IO/E7DMT

332 **Competing interests:** The authors declare that they have no competing interests

333 **Funding:** This work was conducted as part of the GUIDEME project funded by the German Federal  
334 Ministry of Education and Research (BMBF 01GP2208A). DS received the funding. The funder had no  
335 role in the study design, data collection and analysis, decision to publish, or preparation of the  
336 manuscript.

337 **Authors' contributions:** D.S.: Conceptualization, Funding acquisition, Methodology, Supervision, and  
338 Writing - review & editing.

339 M.-M.P.: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Project  
340 administration, Software, Visualization, and Writing - original draft.

341 **Acknowledgements:** We thank Ulrike Grittner, Sebastian Graf von Kielmansegg, Lucas Augustin, Eva  
342 Winkler, and Annette Rid for their input and feedback at several stages of the project.

343

344

345

346

347

348

### List of Abbreviations

349 AKEK – Arbeitskreis Medizinischer Ethikkommissionen

350 IRB – Institutional Review Board

351 REC – Research Ethics Committee

352 WHO – World Health Organization


353

354

355

356


Tables and Figures



357

358 Figure 1. *The 35 Checkpoints associated with the guiding principles of ethical clinical research.*

359



360

361 Figure 2. *Development of resources over time. Note that for 45 resources we were unable to extract a*

362 *year of creation.*



<b>Table 1.</b> Overview of the informational sources			
<b>Language</b>	<b>Name</b>	<b>Identified via</b>	<b>Nr. Resources</b>
<b><i>National umbrella organizations</i></b>			
German	Arbeitskreis Medizinischer Ethik-Kommissionen (AKEK)	Author team	32
German	Swiss Human Research Ethics Committee (Swissethics)	Author team	45
German	Forum Österreicher Ethikkommissionen	Author team	1
German	Technologie- und Methodenplattform für die vernetzte medizinische Forschung e.V.	AKEK	1
German	Bundesinstitute für Arzneimittel und Medizinprodukte	Ethik-Kommission Westfalen-Lippe	1
German	Paul Ehrlich Institute	Ethik-Kommission Westfalen-Lippe	3
English	National Health Service (NHS) Health Research Authority	Author team	10
English	United Kingdom Research and Innovation (UKRI)	Author team, online search	4
English	Canadian Institutes of Health Research	Online search	1
English	SmartIRB	Online search	1
English	National Institute of Health (NIH)	Author team	0
English	Clinical Research Ethics Consultation Collaborative	Online search	1
<b><i>International umbrella organizations</i></b>			
English	World Health Organization (WHO)	Author team	13
English	European Network of Research Ethics Committees (EUREC)	Online search	1
English	Ethics and New Emerging Research Institutions (ENERI)	Online search	1
<b><i>National RECs</i></b>			
German	Ethik-Kommission Westfalen-Lippe	Author team	4
German	Ludwig Maximilian University of Munich (LMU)	Author team	12
German	Hannover Medical School (MHH)	Author team	4
German	Ärztekammer Hamburg	Author team	0
German	University of Cologne	Author team	7
German	Heidelberg University	Author team	5
German	Albert-Ludwigs-University Freiburg	Author team	4
German	University of Vienna	Author team	0
English	Stanford Center for Biomedical Ethics	Author team	31
English	Mayo Clinic	Author team	0
English	Johns Hopkins	Author team	21
English	University Hospital Bristol	Author team	23
English	Royal Stoke	Author team	0
English	Cambridge	Author team	0
English	Oxford	Author team	0
English	University Hospitals Birmingham	Author team	9

**Table 2.** Extracted resources per checkpoint.

Checkpoint	N	Available Resources
<b>Study Governance/Management</b> 24		
1. Identification, study registration, and reporting	0	None
2. Study leadership/ investigators, study/examination centres	14	- 6 guidelines (examiner qualification, required qualifications) - 6 templates (site suitability, examiner suitability, and investigator CV) - 2 flowcharts (examiner suitability)
3. Sponsor	2	- 2 templates (amendments to be evaluated by sponsor, clinical study agreement)
4. Study financing	2	- 1 tool (transparent cost calculation) - 1 template (transparent cost calculation)
5. Study implementation	5	1 checklist (ancillary review, multi-site studies) 3 guidelines (ancillary review) 1 template (ancillary review, multi-site studies)
6. Conflict of interest	1	- 1 template (financial disclosure)
7. Study committees	0	None
8. Legal regulations	0	None
<b>Research Question, Study Design</b> 32		
9. Question, background, objective, hypotheses, target population	0	None
10. Summary of the current state of knowledge	0	None
11. Participant selection	7	- 3 guidelines (participant recruitment, appropriate language) - 3 templates (recruitment ads, telephone recruitment script) - 1 checklist (recruitment via advertisement)
12. Sample size determination	0	none
13. Study type/ study design	0	none
14. Study protocol/examination plan with timetable, work plan	23	- 15 templates (study protocols for general clinical studies, prospective studies, retrospective studies, qualitative studies, studies with medical devices, studies with in vitro diagnostics, dead body(parts), and humans) - 5 guidelines (study protocols for clinical studies in general, prospective studies, retrospective studies, and qualitative studies) - 3 checklists (general aspects, one with patient reported outcomes)
15. Intervention	1	- 1 template (risk assessment)
16. Control group/ control intervention	0	none
17. Blinding	0	none
18. Study outcomes	0	none
19. Early termination	1	- 1 template (termination of the study including early termination)
<b>Study Participants</b> 99 -		
20. Participant information and informed consent	76	- 51 templates (informed consent forms and study information for various types of research [minimal risk, magnetic resonance imaging, trials with medicinal products, drug trials, trials with biological or genetic materials, trials with radiation], types of participants [consenting adults, children, parents and legal guardians, pregnant people], and situations [expanded access, new information, continued participation, screening, ancillary review]; verbal consent; general consent This also included one template for general consent)

Continued

**Table 2.** continued

<b>Checkpoint</b>	<b>N</b>	<b>Available Resources</b>
20. Participant information and informed consent (continued)		- 14 guidelines (requirements participant information and informed consent forms, electronic consent, non-native speaker, appropriate language, research with children) - 6 checklists (informed consent) - 3 glossaries (laypeople language) - 2 tools (participant information, informed consent)
21. Inability to consent	5	- 3 guidelines (surrogate decision makers, post-mortem studies) - 2 templates (informed consent forms for surrogate decision makers)
22. Other vulnerable groups of study participants	8	- 5 guidelines (research with minors, language for people with learning disability, emergency research) - 2 templates (pregnancy report forms) - 1 checklist (research with minors)
23. Insurance	6	- 3 guidelines (participant insurance, general requirements) - 3 templates (liability insurance, confirmation of insurance)
24. Financial arrangements	1	- 1 guideline (compensation)
25. Medical care/psychosocial support	0	
26. Body (bio)materials, genetic examination/analysis	3	- 2 guidelines (evaluation of biobanks) - 1 template (data repository genetic data)
<b>Documentation, Analysis, Reporting</b>	<b>49</b>	-
27. Data protection	10	- 3 guidelines (GDPR, biobanks) - 6 templates (GDPR, data leaks, participant information, biological material) - 1 software (anonymization)
28. Data collection	5	- 4 templates (data management plan, data collection form) - 1 guideline (review data management plan)
29. Data preservation	9	- 6 templates (data sharing, archiving) - 3 guidelines (data sharing, retention period, databases and required approvals)
30. Control of study implementation	0	
31. Documentation	9	- 8 templates (handover plan, amendment log, training log, site screening log, adverse event log) - 1 guideline (essential research documentation)
32. Adverse events, side effects	14	- 12 templates (reporting, follow up) - 2 guidelines (health related findings, safety update report)
33. Analysis	1	- 1 flowchart (biometry)
34. Scientific publications, communication of results	1	- 1 template (publication and conference presentations)
35. Ethical justifiability	0	
Other	29	

## References

1. McNair L. Ethical and regulatory oversight of clinical research: The role of the Institutional Review Board. *Exp Biol Med*. April 2022;247(7):561–6.
2. Hemminki E. Research ethics committees in the regulation of clinical research: comparison of Finland to England, Canada, and the United States. *Health Res Policy Syst*. 19. Januar 2016;14(1):5.
3. The National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. The Belmont Report [Internet]. Verfügbar unter: [https://www.hhs.gov/ohrp/sites/default/files/the-belmont-report-508c\\_FINAL.pdf](https://www.hhs.gov/ohrp/sites/default/files/the-belmont-report-508c_FINAL.pdf)
4. World Medical Association. World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. *JAMA*. 27. November 2013;310(20):2191–4.
5. Council for International Organizations of Medical Sciences. International ethical guidelines for health-related research involving humans. 4th Edition. Geneva: CIOMS; 2016.
6. U.S. Department of Health and Human Services. Protection of Human Subjects. 45 C.F.R. 46.
7. Arbeitskreis Medizinischer Ethikkommissionen in der Bundesrepublik Deutschland e.V. AKEK - Arbeitskreis Medizinischer Ethik-Kommissionen [Internet]. 2023 [zitiert 13. November 2023]. Verfügbar unter: <https://www.akek.de>
8. World Health Organization. Research Ethics Review Committee (ERC). 2023 [zitiert 13. November 2023]. Guidelines on submitting research proposals for ethics review. Verfügbar unter: <https://www.who.int/groups/research-ethics-review-committee/guidelines-on-submitting-research-proposals-for-ethics-review>
9. Emanuel EJ, Wendler D, Grady C. An ethical framework for biomedical research. *Oxf Textb Clin Res Ethics*. 2008;123–35.
10. Raspe HH, Hüppe A, Strech D, Taupitz J. Empfehlungen zur Begutachtung klinischer Studien durch Ethik-Kommissionen. 2., überarb. und aktualisierte Aufl. Köln: Deutscher Ärzte-Verlag; 2012. 257 S. (Medizin-Ethik).
11. Bundesinstitute für Arzneimittel und Medizinprodukte. Deutsches Register Klinischer Studien. 2023 [zitiert 13. November 2023]. Deutsches Register Klinischer Studien. Verfügbar unter: [https://www.bfarm.de/DE/Das-BfArM/Aufgaben/Deutsches-Register-Klinischer-Studien/\\_node.html](https://www.bfarm.de/DE/Das-BfArM/Aufgaben/Deutsches-Register-Klinischer-Studien/_node.html)
12. National Library of Medicine. Support Materials [Internet]. 2023 [zitiert 13. November 2023]. Verfügbar unter: <https://classic.clinicaltrials.gov/ct2/manage-recs/resources>
13. Thiele C, Hirschfeld G. Registration quality and availability of publications for clinical trials in Germany and the influence of structural factors. *PLOS ONE*. 9. Mai 2022;17(5):e0267883.
14. Viergever RF, Karam G, Reis A, Ghersi D. The Quality of Registration of Clinical Trials: Still a Problem. *PLOS ONE*. 10. Januar 2014;9(1):e84727.
15. Du Sert NP, Bamsey I, Bate ST, Berdoy M, Clark RA, Cuthill IC, u. a. The Experimental Design Assistant. *Nat Methods*. November 2017;14(11):1024–5.

16. Anderson EE, Johnson A, Lynch HF. Inclusive, engaged, and accountable institutional review boards. *Account Res.* 2023;0(0):1–9.
17. Lynch HF, Eriksen W, Clapp JT. “We measure what we can measure”: Struggles in defining and evaluating institutional review board quality. *Soc Sci Med.* 1. Januar 2022;292:114614.
18. Seykora A, Coleman C, Rosenfeld SJ, Bierer BE, Lynch HF. Steps toward a System of IRB Precedent: Piloting Approaches to Summarizing IRB Decisions for Future Use. *Ethics Hum Res.* 2021;43(6):2–18.